IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TARELLA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.472
NA - Nord America 6.475
AS - Asia 5.808
SA - Sud America 756
AF - Africa 163
OC - Oceania 83
Continente sconosciuto - Info sul continente non disponibili 15
Totale 23.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.204
GB - Regno Unito 3.706
CN - Cina 2.184
DE - Germania 2.144
IT - Italia 1.464
SG - Singapore 1.169
RU - Federazione Russa 652
HK - Hong Kong 624
SE - Svezia 589
BR - Brasile 557
IN - India 390
IE - Irlanda 349
TR - Turchia 347
FR - Francia 308
KR - Corea 252
NL - Olanda 224
JP - Giappone 210
VN - Vietnam 203
ES - Italia 198
CA - Canada 163
UA - Ucraina 156
FI - Finlandia 146
ID - Indonesia 145
CH - Svizzera 107
EU - Europa 103
PL - Polonia 91
AU - Australia 76
MX - Messico 71
CO - Colombia 55
DK - Danimarca 49
CI - Costa d'Avorio 46
GR - Grecia 46
AR - Argentina 42
BE - Belgio 42
AT - Austria 40
TW - Taiwan 37
BD - Bangladesh 30
EC - Ecuador 30
HR - Croazia 26
PK - Pakistan 26
IL - Israele 25
CZ - Repubblica Ceca 24
MA - Marocco 22
SA - Arabia Saudita 22
PT - Portogallo 21
PE - Perù 20
PH - Filippine 20
RO - Romania 19
ZA - Sudafrica 19
CL - Cile 17
IR - Iran 17
IQ - Iraq 16
KE - Kenya 15
TH - Thailandia 15
VE - Venezuela 15
LT - Lituania 14
TN - Tunisia 14
EG - Egitto 13
ET - Etiopia 13
MY - Malesia 13
JO - Giordania 12
UZ - Uzbekistan 12
PY - Paraguay 11
NO - Norvegia 10
BA - Bosnia-Erzegovina 7
BY - Bielorussia 7
NZ - Nuova Zelanda 7
TT - Trinidad e Tobago 6
BO - Bolivia 5
EE - Estonia 5
HN - Honduras 5
NP - Nepal 5
SN - Senegal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
GE - Georgia 4
HU - Ungheria 4
OM - Oman 4
PA - Panama 4
SI - Slovenia 4
UY - Uruguay 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
KZ - Kazakistan 3
LB - Libano 3
LC - Santa Lucia 3
MK - Macedonia 3
NG - Nigeria 3
RS - Serbia 3
SC - Seychelles 3
AP - ???statistics.table.value.countryCode.AP??? 2
AZ - Azerbaigian 2
DZ - Algeria 2
GH - Ghana 2
GT - Guatemala 2
IS - Islanda 2
KG - Kirghizistan 2
KW - Kuwait 2
Totale 23.834
Salva come PNG Salva come JPEG
Città #
Southend 3.358
Frankfurt am Main 1.460
Singapore 631
Hong Kong 542
Milan 459
Ashburn 457
Seattle 430
Chandler 414
Beijing 401
Princeton 348
Dublin 345
Fairfield 337
Dallas 295
Wilmington 293
Council Bluffs 207
Woodbridge 184
Houston 150
Los Angeles 148
Bengaluru 140
Redwood City 137
Redmond 125
Ann Arbor 117
Des Moines 117
Nanjing 116
Cambridge 111
Shanghai 111
Jacksonville 110
Santa Clara 109
Buffalo 107
Guangzhou 107
Hanover 105
Moscow 104
Hefei 103
Dearborn 95
Mountain View 95
Jakarta 93
Tokyo 84
Sakarya 83
Columbus 80
Berlin 78
Hangzhou 70
Toronto 70
Tianjin 66
Serra 63
The Dalles 60
Warsaw 58
Phoenix 54
São Paulo 54
Barcelona 53
Rome 53
Shenyang 53
Chicago 49
Boardman 48
New York 48
Nuremberg 47
Seoul 47
Cangzhou 45
London 45
Abidjan 44
Ho Chi Minh City 44
Jinan 44
Somerville 44
Istanbul 43
Bogotá 41
Hanoi 41
Andover 39
Ottawa 38
Nanchang 37
Central District 36
Turin 34
Hebei 33
Paris 33
San Diego 33
Helsinki 32
Shenzhen 32
Changsha 29
Madrid 28
Lugano 27
Trieste 27
Wuhan 27
Athens 25
Mumbai 25
Brussels 24
Zhengzhou 23
Belo Horizonte 22
Dong Ket 22
Falls Church 22
Fuzhou 22
Munich 22
Vienna 22
Bologna 21
Boston 20
Jiaxing 20
Melbourne 19
Chengdu 18
Taipei 18
San Francisco 17
Silver Spring 17
Delhi 16
Kiez 16
Totale 14.966
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 1.918
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas 832
Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art 632
The issue of refractory disease in follicular and other lymphoma subtypes 392
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma 345
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 343
[¹⁸ F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma [$\less$sup$\greater$18$\less$/sup$\greater$F]-{FDG} {PET} radiomic model as prognostic biomarker in diffuse large B-cell lymphoma] 295
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 286
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 270
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 268
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors : a single-center experience 240
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 234
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells 224
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 212
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 212
Brief chemoimmunotherapy rituximab ®-FND +/- R maintenance is effective and safe newly diagnosed follicular lymphoma elderly patients : an intergruppo italiano linfomi (IIL) randomized trial 207
Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival 203
Brief chemoimmunoterapy rituximab (R)-FND ± R maintenance as first line treatment in elderly patients with advanced follicular lymphoma (FL) : preliminary analysis of a prospective randomized IIL trial 198
Brief chemoimunotherapy with rituximab (R)- Find ± R maintenance as first treatment in adevanced follicular lymphoma (FL) in elderly : preliminary analysis of a prospective randomized trial 198
Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis : A rare and life-treating condition 194
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation 193
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma 192
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas : pre-transplant disease status and histotype heavily influence outcome 190
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion : results from the National Registry of the Italian Drug Agency 182
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL 181
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 180
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term 179
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 177
Haploidentical cellular therapy in elderly patients with acute myeloid leukemia : description of its use in high risk patients 177
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial) 174
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 173
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs 173
Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting : Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes 171
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 171
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 171
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo 170
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab : a 20-year retrospective follow-up study in patients with lymphoma 168
Rituximab (R) maintenance versus observation after short term chemoimmunotherapy R-Find as first line treatment in elderly patients with advanced follicular lymphoma (FL) : updated results and safety of the maintenance of an Intergruppo Italiano Linfomi (ILL) randomized trial 164
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study 164
Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation 161
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade 160
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 160
Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial 160
Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 160
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma) 157
A multicentre trial G-CSF in Amyotrophic Lateral Sclerosis 154
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation 154
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis : the superior disease control of R-HDS does not translate into an overall survival advantage 154
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 152
A phase I-II multicenter trial on G-CSF in ALS: final results and prospectives 150
Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density : a More Advantageous Method for Clinical Use 148
A phase I-II multicentre study on G-CSF in Amyotrophic Lateral Sclerosis 147
Bone marrow transplantation for lymphoma CR1 147
Primary mediastinal large B-cell lymphoma (PMLBCL) : long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B 147
HHV8-negative effusion-based large B cell lymphoma arising in chronic myeloid leukemia patients under dasatinib treatment : A report of two cases 144
Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas 142
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles : long-term results of the GITIL/FIL HD 0607 trial 142
Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimula patients with Amyotrophic Lateral Sclerosis: results from a multicenter prospective trial 141
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial 141
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 140
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 140
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial 139
Reduced intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin’s and Hodgkin’s lymphomas 138
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 137
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial 135
Minced umbilical cord fragments as a source of cells for orthopaedic tissue engineering: an in vitro study 134
Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment 134
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study 132
A phase I-II Multicenter Study on G-CSF in ALS: Clinical and Hematological Results 131
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies 130
Influence of Donor and Recipient Gender on Telomere Maintenanceafter Umbilical Cord Blood Cell Transplantation: A Study by the GruppoItaliano Trapianto Di Midollo Osseo 130
Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy 129
The hidden genomic landscape of acute myeloid leukemia : Subclonal structure revealed by undetected mutations 129
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia 123
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study 122
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting : evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 121
CD34-positive cells: biology and clinical relevance 121
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) 121
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma : a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence 119
Successful second autologous engraftment after long duration storage of hematopoietic stem cells 119
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 119
Long-term lymphoma survivors following high-dose chemotherapy and autograft : evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir 118
Risk-assessment in diffuse large cell lymphoma at first relapse : a study by the Italian Intergroup for Lymphomas 118
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting 117
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 116
Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome 116
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients 115
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies 114
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma 114
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 112
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 111
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma 111
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement : Final Results of a Multicenter Phase II Trial 110
Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF 109
Prognostic impact of baseline immunologic profile in aggressive b-cell non-hodgkin's lymphomas 109
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms : a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 108
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment 107
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma 107
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting 107
[Clinical use of hematopoietic growth factors] 106
Totale 19.042
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.492
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.492
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.072 0 0 0 0 251 275 150 144 331 245 497 179
2021/20222.450 194 147 258 150 228 110 136 215 269 210 130 403
2022/20232.439 343 161 166 207 229 472 95 157 268 81 140 120
2023/20242.751 146 178 161 111 330 145 282 272 133 255 368 370
2024/20254.314 322 440 235 361 302 209 170 409 235 360 361 910
2025/20262.982 656 465 884 738 239 0 0 0 0 0 0 0
Totale 24.878